ANGLE is a specialist medtech company commercialising the patented ParsortixTM liquid biopsy system to harvest cancer cells from patient blood for analysis to deliver personalised cancer care.

The product is being sold for research use and clinical applications are being developed for ovarian and breast cancers.  A CE Mark is in place in Europe and FDA authorisation is in process for the United States.

ANGLE is listed on the London Stock Exchange AIM market (AGL.L) and on the OTC-QX in New York (ANPCY).